Skip to main content

Table 1 Patient characteristics of advanced (stage II–IV) esophageal cancer patients

From: Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma

  Chemotherapy Chemoradiotherapy
Characteristics All patients Cis/ 5-Fu Doc/ 5-Fu Radio alone Cis/ 5-Fu/ Radio Doc/ 5-Fu/ Radio
Patients, No. (%) 145 (100) 35 (24.1) 38 (26.2) 12 (8.3) 30 (20.7) 30 (20.7)
Age, y median (range) 62 (44-84) 60 (48-81) 61 (45-78) 68 (44-83) 63 (45-74) 61 (52-84)
Sex (%)       
Males 92 (63.4) 25 (27.2) 24 (26.1) 6 (6.5) 19 (20.6) 18 (19.6)
Females 53 (36.6) 10 (18.9) 14 (26.4) 6 (11.3) 11 (20.8) 12 (22.6)
ECOG, PS (%)       
0-1 133 (91.7) 32 (24.1) 34 (25.6) 12 (9.0) 27 (20.3) 28 (21.0)
2 12 (8.3) 3 (25.0) 4 (33.3) 0 (0.0) 3 (25.0) 2 (16.7)
TNM stage (%)       
II 28 (19.3) 0 (0.0) 0 (0.0) 12 (42.9) 15 (53.6) 1 (3.5)
III 47 (32.4) 2 (4.2) 1 (2.1) 0 (0.0) 15 (31.9) 29 (61.7)
IV 70 (48.2) 33 (47.1) 37 (52.8) 0 (0.0) 0 (0.0) 0 (0.0)
G stage (%)       
G1 20 (13.8) 4 (20.0) 3 (15.0) 8 (40.0) 3 (15.0) 2 (10.0)
G2 90 (62.1) 25 (27.7) 24 (26.7) 3 (3.3) 24 (26.7) 14 (15.6)
G3 35 (24.1) 6 (17.1) 11 (31.4) 1 (2.9) 3 (8.6) 14 (40.0)
JWA median (range) 2.4(0.0002-126.0) 3(0.001-29.1) 2.2(0.0002-126.0) 3.9(0.3-67.8) 3.2(0.0014-50.1) 2.5(0.001-34.8)
XRCC1 median (range) 8.6(0.03-1410.4) 11.3(0.04-190.7) 5.5(0.03-211.7) 11.9(0.9-327.6) 9(0.1-1410.4) 7.3(0.03-64.3)
BRCA1 median (range) 11.4(0.4–70.0) 10.2(0.4–70.0) 10.9(0.6–44.9) 10.3(0.4–44.2) 11.4(1.2-62.9) 12.2(2.0–58.9)
Response rate (CR + PR), No. (%) 50 (68.5) 60 (83.3)
Median OS (months, 95%CI) 13 (11.3-14.7) 13.5 (11.3-15.7)
  1. Cis = cisplatin; 5-Fu = 5-fluorouracil; Doc = docetaxel; ECOG = Eastern Cooperative Oncology Group; PS = Performance status; G = differentiation grade; CR = complete response; PR = partial response; OS = overall survival; CI = confidence interval; y = years.